Since the first descriptions of their active functions more than ten years ago, small non-coding RNA species termed microRNA (miRNA) have emerged as essential regulators in a broad range of adaptive and maladaptive cellular processes.
Introduction
The most well-studied sequences in the human genome are those of protein-coding genes, with the coding exons of these genes comprising approximately 1.5% to 2% of the genome. 1) Recently, epigenetic alterations of the genome (e.g., DNA methylation) and the transcriptome (e.g., repression by non-coding RNA) have been recog- Fig. 1 . MicroRNA (miRNA) biogenesis and mechanism of action. MiRNAs undergo several nuclear and cytosolic processing steps before maturation to a biologically active form (19-24 nt) . After processing, the mature miRNA is incorporated into the RNA induced silencing complex (RISC). Through binding to the complementary sites in the 3' untranslated region of their target genes, miRNA promote down regulation of the protein synthesis via translational repression or messenger RNA (mRNA) degradation.
rect targets of such miRNA. 4, 5) MiRNAs are genomically encoded either as single genes ("intergenic"), as a polycistronic family, or as a gene embedded in an intron of a protein-coding gene ("intronic"). Upon transcription to an approximately 1,000 nucleotide precursor (primary miRNA or pri-miRNA), several nuclear and cytosolic processing steps occur leading to maturation to a mature, biologically active double stranded miRNA duplex, consisting of a prototypical active strand that binds target transcripts for gene repression and an "inactive" strand ( Fig. 1) . The mature miRNA is incorporated into the RNA-induced silencing complex including the RNA-binding protein Argonaute 2 which is instrumental in mediating the recognition and binding of mature miRNA with its target mRNA transcript(s). 6) At the 5' end of each miRNA strand exists a "seed sequence" (at positions [2] [3] [4] [5] [6] [7] [8] which is an important determinant for complementary strand target sequence binding, typically at the 3' untranslated region (3'UTR) of the target mRNA transcript.
The remainder of the miRNA sequence typically binds imperfectly, creating bulges and mismatches in the miRNA:mRNA heteroduplex. 7, 8) Therefore, a single miRNA sequence can target hundreds of mRNAs by low miRNA-target complementarity. 9) Furthermore, more than one miRNA can cooperatively bind to the same 3'UTR and, thus, affect a stronger action. 10) As a result of such binding, a miRNA can promote the specific down-regulation of a cadre of mRNA targets, through translational Degradation degradation repression and/or mRNA degradation. 11, 12) In experiments involving both cultured cardiovascular cell types and rodent models of cardiovascular disease, specific gain-and loss-of-function studies of individual miRNA have elucidated their distinct roles in cardiovascular development and physiological function. Overall, miRNA tend to act by "fine tuning" the regulation of gene expression, disruption of which can have dramatic phenotypic consequences especially under stressful conditions. 13) Accordingly, multiple miRNA have been implicated in cardiomyocyte biology such as those involved in myocardial fibrosis, infarction, and hypertrophy ( Fig. 2A) . 14, 15) Several miRNA have also been identified as modulators of systemic vascular remodeling, such as atherosclerosis, vasomotor tone and hypertension, and neointimal formation (Fig. 2B) . 16, 17) However, the importance of miRNA in the pulmonary vasculature is just becoming defined. Here, we aim to review our basic understanding of the molecular mechanisms important in pulmonary vascular diseases such as pulmonary hypertension with the intent to correlate the biology of miRNA with these processes. Consequently, we hope to emphasize the clinical importance of studying miRNA in this context, providing a platform for discovering new molecular mechanisms of pulmonary vascular disease, identifying novel miRNA biomarkers of disease, and potentially determining putative miRNA-based therapeutic targets to ameliorate, regress, or prevent pulmonary hypertension.
Pulmonary hypertension and its known molecular pathogenic mechanisms demonstrating that pulmonary vasodilator therapy is effective across groups 1 to 4. 21) In this review, we will focus primarily on disease mechanisms directly applicable to these two groups, with possible extrapolation of those principles to other types of PH.
Histopathobiology of pulmonary hypertension
In general, various forms of PH and PAH are marked by a complex panvasculopathy affecting small pulmonary arterioles, marked by the dysregulation of multiple cell types and molecular pathways ( 
MicroRNA and pulmonary vascular disease
Considering the complexity and overlapping nature of MiR-328 directly represses L-type calcium channel-α1C expression, resulting in reduction of pulmonary vasoconstrictive properties. Down-regulation of insulin growth factor 1 receptor may also contribute to pulmonary artery smooth muscle cell apoptosis.
50) MiR-21 down-regulates RhoB and Rho-kinase activity to protect against mechanisms driving PAH. 41) An antagomir directed against miR-20a restored functional bone morphogenetic protein receptor type 2 (BMPR2) signaling preventing PAH. 48) For miR-17, the BMPR2 transcript is a predicted and validated target in cultured vascular cells. 
Validated microRNA controlling pulmonary hypertension
Based on the above screening strategies, a handful of miRNA have been mechanistically validated in their roles controlling PH in rodents and human in vivo (Fig. 6) . RhoB, Rho kinase activity, and PH in vivo. 41) As induced by the interleukin-6/signal transducer and activator of transcription 3 inflammatory pathway, the miR-17-92 cluster can directly target BMPR2 in pulmonary vascular cell types. 46) Furthermore, it was recently demonstrated that a miR-17 inhibitor improved heart and lung functions in the PH mouse and rat models. 47) Similarly, an inhibitor of miR-20a reduced PH in hypoxic mice, potentially through a mechanism involving the rescue of BMPR2 expression. 48) More recently, the smooth muscle-specific miR-145 was found to induce PH in vivo presumably through its down-regulation of multiple targets that influence the contractile phenotype of diseased PASMCs. Further clinical implications of microRNA biology (exosomes, microvesicles, and apoptotic bodies), 55, 56) protein complexes (Argonaute2), 57) 
MicroRNA as therapeutic targets in pulmonary hypertension
As potent and crucial regulators in a wide variety of diseases, miRNAs have been also emerged as novel ther- 48) miR-145, 49) and miR-424/503. 51) Alternatively, in circumstances when miRNAs are down-regulated in the disease state to induce disease, a different approach is needed for pathophenotypic reversal. To increase the active concentration of a specific miRNA, one successful approach has entailed the use of synthetic RNA duplexes designed to mimic the native miRNA (miR mimics). In the monocrotaline-induced PAH rat model, nebulization of miR-204 mimics was reported to reduce disease severity significantly. 44) Although miRNA-based therapy continues to be the subject of substantial investigation in both the academic and biotechnology sectors, a number of challenges remain.
Antisense technology has the potential to induce dose-dependent off-target effects, especially in contexts that entail high concentrations necessary for vascular delivery.
Thus far, the ability to specifically deliver inhibitors to the pulmonary vasculature has yet to be realized without affecting other tissues. The advent of nanoparticle-based therapeutics may further advance the applicability of miRNA inhibition in PH. Biodegradable polymer nanoparticles represent a means to effectively deliver miRNA inhibitors, while minimizing the drawbacks of chemical modification that include systemic sequestration in the liver 70) and much higher doses required to achieve efficacy. 73, 74) Furthermore, by utilizing a technique similar to Cheng et al., 75) 
Conclusion
In summary, as more miRNA targets are identified, we anticipate a substantial increase in our understanding of the molecular actions of various miRNA in PH. Given their pleiotropic actions in modulating multiple gene targets, we suspect that many of these may even serve as central molecular "lynchpins" connecting diverse upstream disease triggers to a common pathologic pulmonary vascular result.
We predict rapid advances in this nascent field of study, including improved methods to integrate network and systems biology with evolving technologies in cell culture and in vivo experimentation with miRNA. As a result, our discovery process will be further accelerated in order to identify more comprehensively all relevant miRNA important in this highly morbid condition, with the ultimate goal of rapidly translating these insights and technology to possible regression, reversal, or prevention of PH.
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